一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Fenofibrate and Dyslipidemia: Still a Place in Therapy?

Published:1 September 2018 DOI: 10.1007/s40265-018-0965-8 PMID: 30159817
Nicola Tarantino, Francesco Santoro, Michele Correale, Luisa De Gennaro, Silvio Romano, Matteo Di Biase, Natale Daniele Brunetti

Abstract

Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fenofibrate 49562-28-9 C20H21ClO4 784 suppliers $5.00-$602.00

Similar articles

IF:2.8

Gibberellic acid in plant: still a mystery unresolved.

Plant Signaling & Behavior Ramwant Gupta, S K Chakrabarty,etc Published: 1 September 2013
IF:13

Fenofibrate: a review of its use in dyslipidaemia.

Drugs Kate McKeage, Gillian M Keating,etc Published: 1 October 2011
IF:0

Place of alfacalcidol in treatment of osteoporosis and osteoporotic fractures

Medical alphabet N. Toroptsova,?O. Nikitinskaya,etc Published: 25 December 2022
会泽县| 郎溪县| 拜泉县| 淮阳县| 吉林省| 梅州市| 林芝县| 通化市| 宁陕县| 陕西省| 涞源县| 绥化市| 望奎县| 长春市| 尚志市| 长丰县| 通州市| 靖安县| 景德镇市| 临朐县| 栖霞市| 岳西县| 永康市| 阿拉善盟| 固镇县| 青龙| 革吉县| 全州县| 嘉兴市| 页游| 赤峰市| 乡城县| 正阳县| 台南县| 新乡县| 手机| 六安市| 衡南县| 漳浦县| 新龙县| 汉中市|